The estimated Net Worth of Robert B Bazemore is at least 5.63 百万$ dollars as of 25 March 2021. Mr. Bazemore owns over 10,328 units of Epizyme Inc stock worth over 474,260$ and over the last 9 years he sold EPZM stock worth over 984,341$. In addition, he makes 4,173,620$ as President、 Chief Executive Officer、 Director at Epizyme Inc.
Robert has made over 8 trades of the Epizyme Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 10,328 units of EPZM stock worth 81,075$ on 25 March 2021.
The largest trade he's ever made was selling 20,000 units of Epizyme Inc stock on 18 June 2020 worth over 440,000$. On average, Robert trades about 2,052 units every 22 days since 2016. As of 25 March 2021 he still owns at least 322,626 units of Epizyme Inc stock.
You can see the complete history of Mr. Bazemore stock trades at the bottom of the page.
Robert B. Bazemore Jr. serves as President, Chief Executive Officer, Director of the Company. Prior to joining us, from September 2014 to July 2015, Mr. Bazemore served as the Chief Operating Officer of Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare disorders. Prior to joining Synageva, Mr. Bazemore served in increasing levels of responsibility at Johnson & Johnson, a healthcare company, including Vice President, Centocor Ortho Biotech Sales & Marketing from 2008 to 2010, President of Janssen Biotech from March 2010 to October 2013 and Vice President of Global Surgery at Ethicon from October 2013 to September 2014. Prior to Johnson & Johnson, Mr. Bazemore worked at Merck & Co., Inc. for eleven years, where he served in a variety of roles in medical affairs, sales and marketing. Mr. Bazemore is a director of Ardelyx, Inc., a biopharmaceutical company. He received a B.S. in biochemistry from the University of Georgia.
As the President、 Chief Executive Officer、 Director of Epizyme Inc, the total compensation of Robert Bazemore at Epizyme Inc is 4,173,620$. There are no executives at Epizyme Inc getting paid more.
Robert Bazemore is 52, he's been the President、 Chief Executive Officer、 Director of Epizyme Inc since 2015. There are 16 older and 3 younger executives at Epizyme Inc. The oldest executive at Epizyme Inc is Kenneth Bate, 69, who is the Independent Director.
Robert's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.
Over the last 11 years, insiders at Epizyme Inc have traded over 122,255,844$ worth of Epizyme Inc stock and bought 45,285,781 units worth 322,885,823$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Peter J Barris. On average, Epizyme Inc executives and independent directors trade stock every 17 days with the average trade being worth of 394,367$. The most recent stock trade was executed by Grant C. Bogle on 9 August 2022, trading 1,217,500 units of EPZM stock currently worth 1,704,500$.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
Epizyme Inc executives and other stock owners filed with the SEC include: